คำถามที่พบบ่อย

What is Obecabtagene Autoleucel used for?

A CAR-T cell therapy in which a patient's own T cells are engineered to express a chimeric antigen receptor targeting CD19, used to treat relapsed or refractory B-cell acute lymphoblastic leukemia and other B-cell malignancies. The modified cells are infused back into the patient, where they recognize and destroy CD19-positive cancer cells.

Is Obecabtagene Autoleucel an approved drug?

Yes, Obecabtagene Autoleucel is an approved drug. It has reached clinical phase 4. It is classified as a Gene.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

• ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5095440. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.